- Trial phase
- Preclinical
- Time to market
- Not estimable; the asset is now owned by Biossil Labs, which has not announced clinical timelines
- Why 2/10
- SYN-007 was sold by Theriva to Biossil Labs on October 30, 2026, a completed transaction. There is no upcoming binary catalyst for this drug at Theriva; the asset is no longer in its pipeline. ImpactScore is low because the drug is preclinical, already divested, and represents no further binary risk or opportunity for TOVX stock.
SYN-007 is no longer part of Theriva Biologics. The sale to Biossil Labs closed October 30, 2026. Investors should watch Theriva's Q3 2026 earnings on November 10 for cash runway details and updates on VCN-01, the company's sole remaining pipeline asset. Any future SYN-007 value to Theriva depends entirely on Biossil's ability to advance the program, over which Theriva has no control.
Price Chart
Executive Summary
SYN-007 is a preclinical delayed-release oral formulation of the beta-lactamase enzyme ribaxamase, designed to protect the gut microbiome from damage during oral antibiotic therapy. Theriva Biologics (TOVX) sold SYN-007, along with the rest of its antibiotic-degrading enzyme portfolio, to OpenAI-backed Biossil Labs on October 30, 2026 for $350K upfront plus up to $91M in contingent milestones and royalties. Theriva no longer controls or develops SYN-007; the company is now focused solely on its VCN-01 oncolytic adenovirus platform for cancer. For a TOVX investor, SYN-007 is a historical asset with no upcoming catalysts tied to the company.
How It Works
SYN-007 is an oral enzyme (beta-lactamase) that breaks down certain antibiotics in the gut. It is designed to be taken together with oral antibiotics like amoxicillin to protect the natural gut bacteria from being wiped out, while not interfering with the antibiotic's absorption into the bloodstream. It is a reformulated, delayed-release version of an earlier drug called SYN-004 (ribaxamase).
Trial Status
SYN-007 never entered human clinical trials. Preclinical proof-of-concept was demonstrated in dogs, where SYN-007 co-administered with oral amoxicillin/clavulanate protected the gut microbiome without affecting systemic antibiotic absorption. The parent compound SYN-004 (ribaxamase) had reached Phase 2b for preventing C. difficile infection with IV antibiotics. SYN-007 was designed as a follow-on reformulation for use with oral antibiotics.
The Two-Sided Case
Upcoming Catalysts
- None for Theriva: SYN-007 was sold to Biossil Labs on October 30, 2026, removing it from Theriva's pipeline. Future development decisions rest with Biossil (an OpenAI-backed startup).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Theriva Biologics, Inc. 8-K TOVX ·Originating report